CN116783484A - 检测前列腺癌的罹患可能性的方法 - Google Patents

检测前列腺癌的罹患可能性的方法 Download PDF

Info

Publication number
CN116783484A
CN116783484A CN202180089607.XA CN202180089607A CN116783484A CN 116783484 A CN116783484 A CN 116783484A CN 202180089607 A CN202180089607 A CN 202180089607A CN 116783484 A CN116783484 A CN 116783484A
Authority
CN
China
Prior art keywords
ion
prostate cancer
group
subject
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180089607.XA
Other languages
English (en)
Chinese (zh)
Inventor
尾添淳文
小林健太郎
高桥康彦
松永光平
佐藤孝明
水谷阳一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanye, University of
National Institute of Advanced Industrial Science and Technology AIST
Sumitomo Chemical Co Ltd
Original Assignee
Lanye, University of
National Institute of Advanced Industrial Science and Technology AIST
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanye, University of, National Institute of Advanced Industrial Science and Technology AIST, Sumitomo Chemical Co Ltd filed Critical Lanye, University of
Publication of CN116783484A publication Critical patent/CN116783484A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7206—Mass spectrometers interfaced to gas chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8624—Detection of slopes or peaks; baseline correction
    • G01N30/8631—Peaks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
CN202180089607.XA 2021-01-07 2021-12-24 检测前列腺癌的罹患可能性的方法 Pending CN116783484A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021001676 2021-01-07
JP2021-001676 2021-01-07
PCT/JP2021/048082 WO2022149487A1 (ja) 2021-01-07 2021-12-24 前立腺がんの罹患の可能性を検査する方法

Publications (1)

Publication Number Publication Date
CN116783484A true CN116783484A (zh) 2023-09-19

Family

ID=82357872

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180089607.XA Pending CN116783484A (zh) 2021-01-07 2021-12-24 检测前列腺癌的罹患可能性的方法

Country Status (7)

Country Link
US (1) US20240085400A1 (https=)
EP (1) EP4276456A4 (https=)
JP (1) JP7769179B2 (https=)
CN (1) CN116783484A (https=)
AU (1) AU2021417970A1 (https=)
TW (1) TW202242412A (https=)
WO (1) WO2022149487A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108344830A (zh) * 2017-01-22 2018-07-31 中国科学院大连化学物理研究所 用于诊断前列腺癌的尿样组合标志物及检测试剂盒和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515270A (ja) * 2009-12-22 2013-05-02 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝学的プロファイリング
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
US20160025734A1 (en) * 2014-07-23 2016-01-28 Children's Medical Center Corporation Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate
JP2017203649A (ja) * 2016-05-09 2017-11-16 国立大学法人大阪大学 前立腺がん判定方法
US10908162B2 (en) * 2017-10-27 2021-02-02 The Board Of Regents Of The University Of Texas System Methods related to volatile compounds in genitourinary cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108344830A (zh) * 2017-01-22 2018-07-31 中国科学院大连化学物理研究所 用于诊断前列腺癌的尿样组合标志物及检测试剂盒和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARY L. HOROWITZ 等: "《EP28-A3C，Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory;Approved Guideline—Third Edition》", 31 October 2010, 美国临床和实验室标准协会CLSI, pages: 1 - 72 *
中国合格评定国家认可委员会: "CNAS-CL02-A003，医学实验室质量和能力认可准则在临床化学检验领域的应用说明", 1 March 2018, pages: 1 - 7 *
吴骋等: "《医学科研设计与统计分析》", vol. 01, 31 August 2020, 中国统计出版社, pages: 130 - 137 *

Also Published As

Publication number Publication date
EP4276456A4 (en) 2025-02-26
TW202242412A (zh) 2022-11-01
JP7769179B2 (ja) 2025-11-13
AU2021417970A1 (en) 2023-07-27
AU2021417970A9 (en) 2024-05-16
WO2022149487A1 (ja) 2022-07-14
JPWO2022149487A1 (https=) 2022-07-14
EP4276456A1 (en) 2023-11-15
US20240085400A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
Jeddi et al. Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer
US20150079078A1 (en) Biomarkers for triple negative breast cancer
EP2580596A1 (en) Methods to diagnose liver diseases
JP2019049557A (ja) 癌療法を示すためのｓｒｍアッセイ
WO2010002911A2 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
JP6983221B2 (ja) 大腸癌の併用検査
JP6612414B2 (ja) Ｐｄ−ｌ１に対するｓｒｍアッセイ
Igoh et al. Identification and evaluation of potential forensic marker proteins in vaginal fluid by liquid chromatography/mass spectrometry
WO2017066390A1 (en) Methods for using enriched exosomes as a platform for monitoring organ status
JP2019168319A (ja) 小児がん検査用尿中代謝物マーカー
Delmonico et al. Proteomic profile of saliva and plasma from women with impalpable breast lesions
EP3328387A1 (en) Quantifying fr- and gart proteins for optimal cancer therapy
JP2014501918A (ja) ベバシズマブ併用療法のためのマーカーとしてのａｇｔｒ１
Hu et al. Predictive effects of admission white blood cell counts and hounsfield unit values on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
Yang et al. Decreased expression of C-erbB-2 and CXCR4 in breast cancer after primary chemotherapy
CN116783484A (zh) 检测前列腺癌的罹患可能性的方法
JP2008533979A (ja) 生体細胞中の時間依存的な発現を防止するための試薬及び方法
US20140162903A1 (en) Metabolite Biomarkers For Forecasting The Outcome of Preoperative Chemotherapy For Breast Cancer Treatment
El-Najjar et al. A rapid liquid chromatography-tandem mass spectrometry for the quantification of fosfomycin in plasma, urine, and aqueous fluids
Okabayashi et al. mRNA expression of tumor-associated genes in canine grade I meningiomas
Youngblood et al. Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel
JP6769596B2 (ja) 膀胱癌診断薬及び生体試料の判定方法
KR102957337B1 (ko) 반려견의 림프종 진단용 바이오마커
Eibye 156eP Blood based immune-related biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab (CA209-9UP)
WO2019067636A1 (en) ANALYSIS OF PROTEIN EXPRESSION FOR THE PROGNOSIS AND TREATMENT OF BREAST CANCER

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination